Treatment of heart failure and related conditions
AssigneeTufts Medical Center, Inc.
InventorsNavin K. Kapur, Richard H. Karas
Life of this patent
Estimating the term…
Abstract
Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGFβ1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGFβ1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGFβ1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.
Claims40
A method for treating or prophylactically treating heart failure, left ventricle dysfunction, right ventricle dysfunction, pulmonary hypertension, cardiomyopathy, acute myocardial infarction, or post myocardial infarction in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition that inhibits Endoglin activity signaling.
5-7. (canceled)
(canceled)
A method for reducing fibrosis in a subject, said method comprising administering to said subject an effective amount of a composition that inhibits Endoglin activity.
22-24. (canceled)
(canceled)
Dependencies are inferred from the claim text.